B. Infantis Supplementation to Improve Immunity in Infants Exposed to HIV

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Hiv, Vaccine Reaction, Microbial Colonization, Infant Development

In brief

The primary objectives of this study are to evaluate the effect of early-life B. infantis Rosell®-33 supplementation in infants exposed to HIV on: * gut microbiome composition and diversity at 4 weeks of life * markers of intestinal inflammation and microbial translocation at 4 weeks of life * Th1 cytokine responses to BCG at 7 weeks and 36 weeks of life The secondary objectives include to evaluate the effect of B. infantis Rosell®-33 supplementation on: * longitudinal succession of the gut microbiota composition, diversity and function * relative and absolute abundance of B. infantis in infant stool during the first 36 weeks of life * stool metabolome * T cell subset ontogeny during the first 9 months of life. Exploratory objectives are to evaluate whether B. infantis Rosell®-33 supplementation improves: * infant growth * all-cause morbidity * neurodevelopment during the first 9 months of life * antibody responses to early childhood vaccines

Key facts

Study ID
NCT05923333
Run by
University of Cape Town
People needed
200
Starts
2023-08-11
Expected to finish
2027-06-01
Last updated by the study team
2024-08-22

Who can join

Age: any, up to 50. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.